What is CorneaGen?
CorneaGen stands as a prominent entity in the eye banking and ophthalmology sector, specializing in the provision of premium donor corneal tissue and advanced surgical instrumentation. The company is committed to enhancing surgical outcomes and revolutionizing the treatment of corneal diseases through its comprehensive product portfolio and dedication to patient care. Operating across multiple U.S. locations and through strategic alliances, CorneaGen endeavors to restore sight to a vast number of individuals annually, reinforcing its position as a leader in ocular health innovation.
How much funding has CorneaGen raised?
CorneaGen has raised a total of $42M across 2 funding rounds:
Series A
$5M
Series B
$37M
Series A (2018): $5M, investors not publicly disclosed
Series B (2020): $37M led by Flying L Partners
Key Investors in CorneaGen
Flying L Partners
Flying L Partners is an investment firm that has provided backing to CorneaGen. Their specific investment focus is not detailed but their participation in this round suggests a strategic interest in the healthcare or biotechnology sector.
What's next for CorneaGen?
The recent major strategic investment positions CorneaGen for accelerated growth and expanded market penetration. This capital infusion is expected to fuel further development of innovative surgical products and enhance the company's capacity to supply high-quality corneal tissue. CorneaGen's strategic focus on improving patient outcomes and its established presence in the market suggest a continued expansion of its services and a deepening of its impact on the ophthalmology field. Future developments may include broader geographic reach and advancements in tissue processing technologies.
See full CorneaGen company page
